국가: 영국
언어: 영어
출처: MHRA (Medicines & Healthcare Products Regulatory Agency)
Enalapril maleate
Zentiva Pharma UK Ltd
C09AA02
Enalapril maleate
20mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02050501; GTIN: 5000283605416
Enalapril Maleate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - KEEP THIS LEAFLET. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU ONLY. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet, (see section 4). THIS LEAFLET CONTAINS 1. What Enalapril is and what it is used for 2. What you need to know before you take Enalapril 3. How to take Enalapril 4. Possible side effects 5. How to store Enalapril 6. Contents of the pack and other information 1. WHAT ENALAPRIL IS AND WHAT IT IS USED FOR Enalapril belongs to a group of medicines known as angiotensin-converting enzyme inhibitors ('ACE inhibitors'). It works by causing your blood vessels to relax, making it easier for your heart to pump blood around your body. Enalapril can be used to treat: ● high blood pressure (hypertension) ● heart failure, where the heart has difficulty pumping blood around the body Enalapril can also: ● slow down the development of the symptoms of heart failure, which include shortness of breath, swelling of the ankles and feet, and tiredness after only light activity ● slow down the progress of heart failure ● reduce the need for hospitalisation in patients with heart failure or unstable angina ● reduce the risk of heart attacks occurring in patients with unstable angina If you are not sure why you have been prescribed Enalapril, please ask your doctor. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENALAPRIL DO NOT TAKE ENALAPRIL: ● If you are allergic (hypersensitive) to enalapril, other ACE inhibitors (such as captopril, lisinopril or ramapril), or any of the other ingredients of Enalapril Tablets (see section 6). The symptoms of an allergic reaction may include itching, rash, swel 전체 문서 읽기
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Enalapril 20mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg enalapril (as maleate). Also contains 111.0 mg of lactose per tablet, for a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet. White circular biplanar uncoated tablets with 20 embossed on one face and score line on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of hypertension: All grades of essential hypertension and renovascular hypertension. Treatment of heart failure: In heart failure, Enalapril 20 mg, tablets should be used as an adjunctive therapy with non-potassium-sparing diuretics and, where appropriate, digitalis. Enalapril 20 mg, tablets have been shown to improve symptoms, retard the progression of the disease, and reduce mortality and hospitalisation. Prevention of symptomatic heart failure: When used in asymptomatic patients with left ventricular dysfunction, Enalapril 20 mg, tablets retard the development of symptomatic heart failure, and reduce hospitalisation for heart failure. Prevention of coronary ischaemic events in patients with left ventricular dysfunction: Enalapril 20 mg, tablets reduce both the incidence of myocardial infarction and hospitalisation for unstable angina pectoris. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The absorption of enalapril is not affected by food intake. The dose should be individualised according to the patient profile (see section 4.4) and blood pressure response. Hypertension: The initial dose is 5 to maximally 20 mg, depending on the degree of hypertension and the condition of the patient (see below). Enalapril is given once daily. In mild hypertension, the recommended dose is 5 to 10 mg. Patients with a strongly activated renin-angiotensin-aldosterone system (e.g., renovascular hypertension, salt and/or volume depletion, cardiac decompensation, or severe hypertension) may experience an excessive blood pressure fall following the initial dose. A sta 전체 문서 읽기